Table 1.
Clinicopathological data of the training set and the validation set.
| Variable | Training set (n = 509) | Validation set (n = 1041) |
|---|---|---|
| n(%) | ||
| Age (years) | Median 65 (IQR 58–64) | Median 65 (IQR59-71) |
| Gender | ||
| Female | 181 (36%) | 437 (42%) |
| Male | 328 (64%) | 604 (58%) |
| Stage | ||
| II | 241 (47%) | 369 (35%) |
| III | 268 (53%) | 672 (65%) |
| pT stage | ||
| pT1 | 7 (1%) | 14 (1%) |
| pT2 | 38 (7%) | 65 (6%) |
| pT3 | 352 (69%) | 542 (52%) |
| pT4 | 100 (20%) | 374 (36%) |
| Missing | 12 (2%) | 46 (4%) |
| pN stage | ||
| pN0 | 236 (46%) | 356 (34%) |
| pN1 | 186 (37%) | 477 (46%) |
| pN2 | 74 (15%) | 167 (16%) |
| Missing | 13 (3%) | 41 (4%) |
| Lymphatic invasion | ||
| No | 444 (87%) | 885 (85%) |
| Yes | 48 (9%) | 96 (9%) |
| Missing | 17 (3%) | 60 (6%) |
| Venous vascular invasion | ||
| No | 395 (78%) | 589 (57%) |
| Yes | 97 (19%) | 400 (38%) |
| Missing | 17 (3%) | 52 (5%) |
| Sidedness | ||
| Right | 205 (40%) | 569 (55%) |
| Left | 291 (57%) | 424 (41%) |
| Missing | 13 (3%) | 48 (5%) |
| Microsatellite instability | ||
| MSI-H | 63 (12%) | 124 (12%) |
| MSS | 436 (86%) | 874 (84%) |
| Missing | 10 (2%) | 43 (4%) |
| KRAS | ||
| Wild type | 334 (66%) | 643 (62%) |
| Mutated | 171 (34%) | 314 (30%) |
| Missing | 4 (1%) | 84 (8%) |
| BRAF | ||
| Wild type | 454 (89%) | 836 (80%) |
| Mutated | 54 (11%) | 127 (12%) |
| Missing | 1 (0%) | 78 (8%) |
| CD8+ T-lymphocyte fraction | ||
| Low (<=2.7%) | 208 (41%) | 511 (51%) |
| High (>2.7%) | 301 (59%) | 530 (49%) |
| Stroma fraction | ||
| Low (<56%) | 377 (74%) | 882 (85%) |
| High (>=56%) | 132 (26%) | 159 (15%) |
Abbreviations: IQR, interquartile range; pT stage, pathological tumor stage; pN stage, pathological lymph node stage; MSI-H, microsatellite instability-high; MSS, microsatellite stable.